Cost-utilities Analysis of Polatuzumab Vedotin Combined with Bendamustine and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma Which Is Unsuited for Hematopoietic Stem Cell Transplantation

Abstract

Objectives To evaluate the cost-utilities of Polatuzumab Vedotin (Polivy) combined with bendamustine and rituximab regimen (BR) for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) which is unsuited for hematopoietic stem cell transplantation. Methods From the perspective of the China 's health system, the cost-utilities analysis of BR regimen combined with Polatuzumab Vedotin (Polivy) and BR regimen alone for relapsed/refractory DLBCL which is unsuited for hematopoietic stem cell transplantation was analyzed by using partitioned survival model (PSM). Results Compared with BR regimen alone, BR regimen combined with Polatuzumab Vedotin (Polivy) for relapsed/refractory DLBCL which is unsuited for hematopoietic stem cell transplantation patients can increase 1.1706 QALYs in 15 years, the total cost is increased by 231 117.9 yuan, and the ICUR value is 197 434.7 yuan/QALY. The sensitivity analysis confirmed the robustness of the results. Conclusion In the long run, compared with BR alone, BR combined with Polatuzumab Vedotin (Polivy) doesn’t have cost-effectiveness advantages for relapsed/refractory DLBCL which is unsuited for hematopoietic stem cell transplantation patients.